Head-to-Head drug battle offers hope for rare kidney cancer
NCT ID NCT03541902
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 20 times
Summary
This study compares two FDA-approved drugs, cabozantinib and sunitinib, in people with a rare type of advanced kidney cancer called variant histology renal cell carcinoma. The goal is to see which drug works better at slowing cancer growth and has fewer side effects. About 32 participants will be randomly assigned to receive one of the two drugs, and their health will be tracked over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
-
MD Anderson Regional Care Center-Katy
Houston, Texas, 77094, United States
-
MD Anderson Regional Care Center-Sugar Land
Sugar Land, Texas, 77478, United States
Conditions
Explore the condition pages connected to this study.